

## **Product datasheet for TL314251**

## CA8 Human shRNA Plasmid Kit (Locus ID 767)

## **Product data:**

**Product Type:** shRNA Plasmids

**Product Name:** CA8 Human shRNA Plasmid Kit (Locus ID 767)

Locus ID: 767

Synonyms: CA-RP; CA-VIII; CALS; CAMRQ3; CARP

**Vector:** pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

**Mammalian Cell** 

Selection:

Puromycin

Format: Lentiviral plasmids

Components: CA8 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 767). 5µg

purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 001321837, NM 001321838, NM 001321839, NM 004056, NR 135821, NM 004056.1,

NM 004056.2, NM 004056.3, NM 004056.4, NM 004056.5, BC069794, BC069794.1, BC015531,

BC069744, BC108929, BM462961, NM 004056.6

UniProt ID: P35219

Summary: The protein encoded by this gene was initially named CA-related protein because of sequence

similarity to other known carbonic anhydrase genes. However, the gene product lacks carbonic anhydrase activity (i.e., the reversible hydration of carbon dioxide). The gene product continues to carry a carbonic anhydrase designation based on clear sequence identity to other members of the carbonic anhydrase gene family. The absence of CA8 gene transcription in the cerebellum of the lurcher mutant in mice with a neurologic defect

suggests an important role for this acatalytic form. Mutations in this gene are associated with

cerebellar ataxia, mental retardation, and dysequilibrium syndrome 3 (CMARQ3).

Polymorphisms in this gene are associated with osteoporosis, and overexpression of this gene in osteosarcoma cells suggests an oncogenic role. Alternative splicing results in multiple

transcript variants. [provided by RefSeq, Mar 2016]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.



**OriGene Technologies, Inc.** 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com



## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).